Connor Clark & Lunn Investment Management Ltd. reduced its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 16.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,365 shares of the medical research company's stock after selling 11,763 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in Natera were worth $9,556,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Blue Trust Inc. increased its stake in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares in the last quarter. Versant Capital Management Inc grew its position in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after purchasing an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after purchasing an additional 261 shares during the period. Principal Securities Inc. lifted its holdings in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after purchasing an additional 332 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other news, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the transaction, the chief executive officer now owns 267,629 shares of the company's stock, valued at approximately $44,150,756.13. This represents a 22.69 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John Fesko sold 669 shares of the firm's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $159.60, for a total transaction of $106,772.40. Following the transaction, the insider now directly owns 114,142 shares in the company, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 298,946 shares of company stock valued at $47,803,462. 7.60% of the stock is currently owned by company insiders.
Natera Trading Up 3.1 %
NASDAQ NTRA traded up $4.59 during trading on Wednesday, hitting $150.87. The stock had a trading volume of 2,162,889 shares, compared to its average volume of 1,346,669. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The stock has a 50 day simple moving average of $162.76 and a 200 day simple moving average of $149.26. The stock has a market capitalization of $20.40 billion, a price-to-earnings ratio of -85.72 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.
Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on NTRA. Canaccord Genuity Group reiterated a "buy" rating and set a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. Barclays began coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 price target on the stock. Royal Bank of Canada initiated coverage on Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price on the stock. Piper Sandler increased their price target on Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Finally, Sanford C. Bernstein lifted their price objective on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $178.12.
Read Our Latest Stock Report on Natera
About Natera
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
